Anti-Human C4.4A (301) Rabbit IgG
- Quantity / Tests
- 50 µg
- Species / Antigen
- human
- Host
- rabbit
- Subclass / Clone
- IgG
- Type
- Polyclonal
- Purification
- with Antigen Peptide
- Regulatory Status
- RUO
C4.4A is known to be present in the placenta, skin, esophagus and peripheral mononuclear cells in humans. It is a GPI (glycosylphosphatidylinositol) binding protein which has a similar structure to urokinase receptor (uPAR) and belongs to the Ly-6 family of proteins as does uPAR. While most of Ly-6 family proteins consist of single domains, uPAR is of three cysteine-rich domains. C4.4A is a membrane protein which binds to cell membrane at GPI binding site, and is consisting of two cysteine-rich domains and a cysteine lacking third domain.
C4.4A was first isolated from metastatic rat pancreatic cancer cell lines in 1989, and its human homolog was isolated in 2001. In human malignant tumors, it has been reported that C4.4A is expressed in malignant melanoma, urothelial, lung, esophageal and colon cancer. It is considered that C4.4A mediates invasion and metastasis of cancer cells by binding with laminin and degrading the extracellular matrix in the progress of cancer.
Therefore, immunological detection of C4.4A in cancerous tissue is expected to be an indicator of tumor metastasis.
Distributed by IBL International
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.